title: alpha1-Proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: a randomized, controlled trial.
abstract: BACKGROUND
  An imbalance between increased neutrophil elastase and a decreased antiprotease shield has been suggested as a factor contributing to the development of chronic lung disease (CLD). We hypothesized that administration of alpha1-proteinase inhibitor (A1PI), also known as alpha1-antitrypsin, to premature neonates would prevent CLD.
  
  
  METHODS
  A randomized, placebo-controlled, prospective study of A1PI supplementation was performed. Neonates <24 hours of age with birth weights 600-1000 g on respiratory support, and 1001-1250 g with respiratory distress syndrome (RDS) were eligible. Intravenous A1PI (60 mg/kg) or placebo was infused on days 0, 4, 7, and 14. Primary outcome was CLD in survivors, defined as the need for supplemental oxygen on day 28.
  
  
  RESULTS
  A total of 106 patients were recruited. There were no significant differences between groups in birth weight or incidence of RDS. The incidence of CLD in survivors was lower in the treated group, but the difference did not reach statistical significance (relative risk [RR], 0.79; confidence interval [CI], 0.60-1.02). This beneficial trend persisted at 36 weeks corrected gestational age (RR, 0.48; CI, 0.23-1.00). The incidence of pulmonary hemorrhage was lower in the treated group (RR, 0.22; CI, 0.05-0.98). Other complications were not significantly different between groups.
  
  
  CONCLUSIONS
  In this, the first trial of a protease inhibitor for the prevention of CLD in premature infants, the infusions were well-tolerated. A1PI therapy may impede the development of CLD and appears to reduce the incidence of pulmonary hemorrhage in some neonates born prematurely.
authors.affiliation: University of Toronto, Toronto, Ontario, Canada.
authors.forename: J A
authors.initials: JA
authors.lastname: Stiskal
authors.forename: M S
authors.initials: MS
authors.lastname: Dunn
authors.forename: A T
authors.initials: AT
authors.lastname: Shennan
authors.forename: K K
authors.initials: KK
authors.lastname: O'Brien
authors.forename: E N
authors.initials: EN
authors.lastname: Kelly
authors.forename: R I
authors.initials: RI
authors.lastname: Koppel
authors.forename: D W
authors.initials: DW
authors.lastname: Cox
authors.forename: S
authors.initials: S
authors.lastname: Ito
authors.forename: S L
authors.initials: SL
authors.lastname: Chappel
authors.forename: M
authors.initials: M
authors.lastname: Rabinovitch
mesh_terms: D001724:Birth Weight; D001997:Bronchopulmonary Dysplasia / Q000209:etiology / Q000517:prevention & control*; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors; D008171:Lung Diseases / Q000517:prevention & control; D010102:Oxygen Inhalation Therapy / Q000009:adverse effects; D011446:Prospective Studies; D012121:Respiration, Artificial / Q000009:adverse effects; D012127:Respiratory Distress Syndrome, Newborn / Q000150:complications / Q000628:therapy; D016896:Treatment Outcome; D000515:alpha 1-Antitrypsin / Q000627:therapeutic use*
chemical_list: D000515:alpha 1-Antitrypsin; D019272:Leukocyte Elastase